JP5975886B2 - Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物 - Google Patents

Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物 Download PDF

Info

Publication number
JP5975886B2
JP5975886B2 JP2012557275A JP2012557275A JP5975886B2 JP 5975886 B2 JP5975886 B2 JP 5975886B2 JP 2012557275 A JP2012557275 A JP 2012557275A JP 2012557275 A JP2012557275 A JP 2012557275A JP 5975886 B2 JP5975886 B2 JP 5975886B2
Authority
JP
Japan
Prior art keywords
lda
tumor
cells
fcγ2a
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012557275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529178A (ja
JP2013529178A5 (OSRAM
Inventor
コズボー，ダヌータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of JP2013529178A publication Critical patent/JP2013529178A/ja
Publication of JP2013529178A5 publication Critical patent/JP2013529178A5/ja
Application granted granted Critical
Publication of JP5975886B2 publication Critical patent/JP5975886B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001121—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012557275A 2010-03-11 2011-03-11 Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物 Active JP5975886B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31298210P 2010-03-11 2010-03-11
US61/312,982 2010-03-11
PCT/US2011/028070 WO2011112915A2 (en) 2010-03-11 2011-03-11 Methods and compositions containing fc fusiong proteins for enhancing immune responses

Publications (3)

Publication Number Publication Date
JP2013529178A JP2013529178A (ja) 2013-07-18
JP2013529178A5 JP2013529178A5 (OSRAM) 2014-05-01
JP5975886B2 true JP5975886B2 (ja) 2016-08-23

Family

ID=44564143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557275A Active JP5975886B2 (ja) 2010-03-11 2011-03-11 Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物

Country Status (5)

Country Link
US (1) US9296803B2 (OSRAM)
EP (1) EP2545174B1 (OSRAM)
JP (1) JP5975886B2 (OSRAM)
CN (1) CN102884194B (OSRAM)
WO (1) WO2011112915A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742251T3 (es) 2009-03-16 2020-02-13 Pangu Biopharma Ltd Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2018102375A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
RU2676317C1 (ru) * 2017-08-30 2018-12-27 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ pCXCRs-Fc ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО СЛИТОГО БЕЛКА, ОБЛАДАЮЩЕГО АНТИ-IL-8 АКТИВНОСТЬЮ
CN116375881A (zh) * 2021-12-31 2023-07-04 广州国家实验室 融合蛋白疫苗
CN116059388A (zh) * 2022-07-25 2023-05-05 国家纳米科学中心 一种多肽-化疗药物偶联物、其制备方法和应用
CN117003890B (zh) * 2023-08-09 2024-06-04 成都新诺明生物科技有限公司 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
AU2001252262B2 (en) * 2000-04-13 2006-02-02 Biolife Science Forschungs-und Entwicklungsgesellschaft m.b.H Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
MXPA02010787A (es) * 2000-05-03 2003-07-14 Amgen Inc Peptidos modificados como agentes terapeuticos.
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
CA2696460A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity

Also Published As

Publication number Publication date
US20130011436A1 (en) 2013-01-10
EP2545174A4 (en) 2013-08-21
US9296803B2 (en) 2016-03-29
HK1178935A1 (zh) 2013-09-19
JP2013529178A (ja) 2013-07-18
EP2545174A2 (en) 2013-01-16
EP2545174B1 (en) 2015-11-11
CN102884194A (zh) 2013-01-16
WO2011112915A2 (en) 2011-09-15
CN102884194B (zh) 2015-07-22
WO2011112915A3 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
JP5975886B2 (ja) Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
JP2024099664A (ja) Ｉｌ２アゴニスト
Murata et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen
CA2821080C (en) Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
US7563445B2 (en) CD40 binding molecules and CTL peptides for treating tumors
CN118546960A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN102036677A (zh) 热休克蛋白gp96的疫苗接种及其使用方法
Rashidijahanabad et al. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy
US10934331B2 (en) Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells
WO2010030002A1 (ja) 外来性ｇｉｔｒリガンド発現細胞
KR20040098048A (ko) 4-1ｂｂ 및/또는 ｃｄ40의 생체내 격발을 통한 항종양ｃｔｌ 면역성 유발
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
JP2011513399A (ja) 同種癌細胞による免疫療法
Okano et al. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity
Kaufman et al. Strategies for cancer therapy using carcinoembryonic antigen vaccines
Huang et al. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand
JP7271037B2 (ja) 免疫シナプスを安定化させるキメラ抗原受容体（ｃａｒ）ｔ細胞
Danishmalik et al. Tumor regression is mediated via the induction of HER263-71-specific CD8+ CTL activity in a 4T1. 2/HER2 tumor model: no involvement of CD80 in tumor control
KR20220145337A (ko) 질병 치료용 다중특이적 항체
JP2022539543A (ja) Ｉｌ２アゴニスト
CN116472060A (zh) 抗体疗法
Lou et al. Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1
Nathalie et al. Therapeutic MUC1-based cancer vaccine expressed in flagella-efficacy in an aggressive model of breast cancer
Chung et al. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide
HK1178935B (en) Methods and compositions containing fc fusion proteins for enhancing immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160719

R150 Certificate of patent or registration of utility model

Ref document number: 5975886

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250